MX2009008923A - Compuestos y metodos para modular receptores acoplados por proteina g. - Google Patents

Compuestos y metodos para modular receptores acoplados por proteina g.

Info

Publication number
MX2009008923A
MX2009008923A MX2009008923A MX2009008923A MX2009008923A MX 2009008923 A MX2009008923 A MX 2009008923A MX 2009008923 A MX2009008923 A MX 2009008923A MX 2009008923 A MX2009008923 A MX 2009008923A MX 2009008923 A MX2009008923 A MX 2009008923A
Authority
MX
Mexico
Prior art keywords
compounds
modulating
protein
methods
coupled receptors
Prior art date
Application number
MX2009008923A
Other languages
English (en)
Inventor
Robert Epple
Mihai Azimioara
Ross Russo
Christopher Cow
Victor Nikulin
Gerald Lelais
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of MX2009008923A publication Critical patent/MX2009008923A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/60—Naphthoxazoles; Hydrogenated naphthoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona compuestos y composiciones farmacéuticas de los mismos, que son útiles para modular el receptor 20 acoplado por proteína G (GPR20), y métodos para utilizar dichos compuestos para tratar, aminorar o prevenir una condición asociada con GPR20 anormal o desregulado.
MX2009008923A 2007-02-22 2008-01-08 Compuestos y metodos para modular receptores acoplados por proteina g. MX2009008923A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89117807P 2007-02-22 2007-02-22
PCT/US2008/050507 WO2008103501A1 (en) 2007-02-22 2008-01-08 Compounds and methods for modulating g protein-coupled receptors

Publications (1)

Publication Number Publication Date
MX2009008923A true MX2009008923A (es) 2009-08-28

Family

ID=39522201

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008923A MX2009008923A (es) 2007-02-22 2008-01-08 Compuestos y metodos para modular receptores acoplados por proteina g.

Country Status (11)

Country Link
US (1) US8394841B2 (es)
EP (1) EP2125758A1 (es)
JP (1) JP5175866B2 (es)
KR (1) KR20090113901A (es)
CN (1) CN101646660A (es)
AU (1) AU2008218951B2 (es)
BR (1) BRPI0807552A2 (es)
CA (1) CA2677706A1 (es)
EA (1) EA200901099A1 (es)
MX (1) MX2009008923A (es)
WO (1) WO2008103501A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101273765B1 (ko) * 2008-06-24 2013-06-12 아이알엠 엘엘씨 Ｇ 단백질-커플링된 수용체를 조정하는 화합물 및 방법
JP2012506386A (ja) * 2008-10-21 2012-03-15 メタボレックス， インコーポレイテッド アリールｇｐｒ１２０受容体アゴニストおよびその使用
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
WO2010104195A1 (en) 2009-03-11 2010-09-16 Banyu Pharmaceutical Co.,Ltd. Novel isoindolin-1-one derivative
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CA2905729C (en) * 2013-03-14 2021-11-09 Janssen Pharmaceutica Nv Bicyclic pyrrole derivatives useful as agonists of gpr120
PL3421458T3 (pl) 2013-03-14 2021-04-19 Janssen Pharmaceutica Nv Benzo-skondensowane heterocykliczne pochodne przydatne jako agonisty gpr120
CA2905726C (en) 2013-03-14 2022-05-31 Janssen Pharmaceutica Nv Gpr120 agonists for the treatment of type ii diabetes
US10227360B2 (en) 2014-02-19 2019-03-12 Piramal Enterprises Limited Compounds for use as GPR120 agonists
US9067898B1 (en) 2014-03-07 2015-06-30 Janssen Pharmaceutica Nv Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes
US8912227B1 (en) 2014-03-07 2014-12-16 Janssen Pharmaceutica Nv Bicyclic pyrrole derivatives useful as agonists of GPR120
CA2955919A1 (en) 2014-07-25 2016-01-28 Piramal Enterprises Limited Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof
WO2016038540A1 (en) 2014-09-11 2016-03-17 Piramal Enterprises Limited Fused heterocyclic compounds as gpr120 agonists
CA3121986C (en) * 2014-12-24 2024-04-09 Lg Chem, Ltd. Biaryl derivative as gpr120 agonist
US10941133B2 (en) 2015-02-05 2021-03-09 Piramal Enterprises Limited Compounds containing carbon-carbon linker as GPR120 agonists
CN105477451A (zh) * 2016-01-08 2016-04-13 董仲璧 一种治疗癌症及癌症疼痛、发热的中药组合物
US10800773B2 (en) 2016-09-12 2020-10-13 Integral Health, Inc. Monocyclic compounds useful as GPR120 modulators
EP3509588B1 (en) * 2016-09-12 2023-06-07 Integral Health,Inc. Bicyclic compounds useful as gpr120 modulators
CN107089977B (zh) * 2017-07-09 2018-07-31 王善梅 一种用于治疗艾滋病的药物及其制备方法
CA2995617A1 (en) * 2017-11-03 2019-05-03 Universite De Montreal Heterocyclic mitochondrial activity inhibitors and uses thereof
CN113956213A (zh) * 2021-11-19 2022-01-21 烟台药物研究所 一类2，4-二取代噻唑结构的PPARα/δ双重激动剂及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU510758B2 (en) * 1976-01-19 1980-07-10 The Dow Chemical Company P-benzylaminobenzoic acids
US5591862A (en) 1993-06-11 1997-01-07 Takeda Chemical Industries, Ltd. Tetrazole derivatives, their production and use
JP3466273B2 (ja) * 1993-06-11 2003-11-10 武田薬品工業株式会社 テトラゾール誘導体、その製造法およびそれを含んでなる医薬
CA2202623A1 (en) 1994-10-14 1996-04-25 Hitoshi Nagaoka Azole derivative
GB2328975A (en) * 1997-09-03 1999-03-10 Ford Global Tech Inc Combustion engine with internal EGR
ATE451346T1 (de) * 1998-03-10 2009-12-15 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONNECTION WITH CONDENSED RING
JP4805552B2 (ja) * 2003-05-30 2011-11-02 武田薬品工業株式会社 縮合環化合物
JP4922615B2 (ja) 2003-11-26 2012-04-25 武田薬品工業株式会社 受容体機能調節剤
EP1737809B1 (en) * 2004-02-27 2013-09-18 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
US20090000358A1 (en) 2004-05-04 2009-01-01 Nederlandse Organisatie Voor Toegepastnatuurweten Method of Analysis Using Chromatographic Pre-Separation
PE20060315A1 (es) * 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
PE20060362A1 (es) * 2004-05-24 2006-05-15 Irm Llc Compuestos de oxazol como moduladores de ppar
JP2009514964A (ja) * 2005-11-07 2009-04-09 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｐｐａｒモジュレーターとしての化合物および組成物

Also Published As

Publication number Publication date
US20100035944A1 (en) 2010-02-11
AU2008218951A1 (en) 2008-08-28
JP2010519306A (ja) 2010-06-03
KR20090113901A (ko) 2009-11-02
AU2008218951B2 (en) 2011-11-17
CA2677706A1 (en) 2008-08-28
WO2008103501A1 (en) 2008-08-28
EP2125758A1 (en) 2009-12-02
BRPI0807552A2 (pt) 2014-07-01
US8394841B2 (en) 2013-03-12
CN101646660A (zh) 2010-02-10
EA200901099A1 (ru) 2010-04-30
JP5175866B2 (ja) 2013-04-03

Similar Documents

Publication Publication Date Title
MX2009008923A (es) Compuestos y metodos para modular receptores acoplados por proteina g.
MX2009008921A (es) Derivados de tiazole en la forma de moduladores de receptores acoplados por proteina g.
WO2008033408A3 (en) Methods for identifying compounds that modulate cell signaling and methods employing such compounds
GEP20125506B (en) Glucagon receptor antagonist compounds, compositions containing such compounds and use
TNSN07264A1 (en) Organic compounds
WO2009061652A8 (en) Compounds which modulate the cb2 receptor
MX2009008159A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2011011763A (es) Composiciones plaguicidas.
SG169353A1 (en) Tamper resistant dosage forms
WO2008042571A3 (en) Substituted indole compounds
MX2010006279A (es) 4-fenilpiran-3,5-dionas, 4-feniltiopiran-3,5-dionas y 2-fenil de ciclohexan-1,3,5-trionas como herbicidas.
WO2010008831A3 (en) Compounds and methods for modulating g protein-coupled receptors
EP1962838A4 (en) Farnesoid X RECEPTOR AGONISTS
EP2179598A4 (en) SECURE LOCALIZATION FOR 802.11 NETWORKS WITH FINE GRANULARITY
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
SG178999A1 (en) Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
WO2009016253A3 (en) Cyanomethyl substituted n-acyl tryptamines
TN2011000639A1 (en) Compounds which selectively modulate the cb2 receptor
MX2010002028A (es) Metodos y composiciones para modular celulas t.
TN2010000062A1 (en) Pyrrolidin -2-one derivatives as androgen receptor modulator
IN2012DN02876A (es)
GB2466912A (en) Compositions and methods for treating lysosomal disorders
MY178894A (en) Therapeutic compositions containing macitentan
SG154441A1 (en) Treatment of demyelinating disorders
MX2009007336A (es) Indazoles substituidos con 5-furopiridinona.

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal